Skip to main content

Incannex appoints principal investigators for pivotal IHL-42X trial

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Incannex Healthcare Ltd (ASX:IHL, NASDAQ: IXHL) CEO Joel Latham tells Proactive the company has appointed two highly experienced lead principal investigators for its Phase 2/3 clinical trial of IHL-42X, a treatment for obstructive sleep apnoea (OSA). The investigators, Dr John D Hudson of FutureSearch Trials of Neurology in Austin, Texas, and Dr Russell Rosenberg of Neurotrials Research Inc in Atlanta, Georgia, will play a crucial role overseeing the first clinical trial sites, handling submissions to the FDA and obtaining ethics approval from Institutional Review Boards.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

Jonathan@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/incannex-appoints-principal-investigators-for-pivotal-ihl-42x-trial-508961464

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  246.82
-10.55 (-4.10%)
AAPL  342.56
-6.65 (-1.90%)
AMD  424.39
-64.80 (-13.25%)
BAC  47.04
-1.53 (-3.15%)
GOOG  264.00
-7.02 (-2.59%)
META  560.84
-35.38 (-5.93%)
MSFT  484.52
-13.78 (-2.77%)
NVDA  125.53
-20.45 (-14.01%)
ORCL  101.19
-9.38 (-8.48%)
TSLA  345.82
-28.59 (-7.64%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.